Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets

European Journal of Pharmacology

Volumn 721, Issue 1-3, 2013, Pages 215-224

  Saxena, Aaruni ^b   Balaramnavar, Vishal M ^a   Hohlfeld, Thomas ^b   Saxena, Anil K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Aggregation; Aspirin; Drug drug interaction; Molecular modeling; Thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; DIPYRONE; FLUFENAMIC ACID; IBUPROFEN; MEFENAMIC ACID; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; THROMBOXANE;

ANTICOAGULATION; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; DRUG COMPETITION; DRUG INTERACTION; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROGEN BOND; LIPOGENESIS; MOLECULAR DOCKING; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

AGGREGATION; ASPIRIN; DRUG/DRUG INTERACTION; MOLECULAR MODELING; THROMBOXANE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PLATELETS; CATALYTIC DOMAIN; CYCLOOXYGENASE 1; DRUG INTERACTIONS; HUMANS; MOLECULAR DOCKING SIMULATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS;

EID: 84890116140     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.09.032     Document Type: Article

References (38)

1. A. Alagha, E. Moman, M.F. Adamo, K.B. Nolan, and A.J. Chubb Design, synthesis and evaluation of aspirin analogues having an additional carboxylate substituent for antithrombotic activity Bioorganic & Medicinal Chemistry Letters 19 2009 4213 4216
2. P. Anzellotti, M.L. Capone, A. Jeyam, S. Tacconelli, A. Bruno, P. Tontodonati, L. Di Francesco, L. Grossi, G. Renda, G. Merciaro, P. Di Gregorio, T.S. Price, L.A. Garcia odriguez, and P. Patrignani Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences Arthtitis and Rheumatism 63 2011 850 859
3. A. Bernareggi Clinical pharmacokinetics of nimesulide Clinical Pharmacokinetics 35 1998 247 274 (Pubitemid 28491213)
4. G.G. Biondi-Zoccai, M. Lotrionte, P. Agostoni, A. Abbate, M. Fusaro, F. Burzotta, L. Testa, I. Sheiban, and G. Sangiorgi Systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease European Heart Journal 27 2006 2667 2674 (Pubitemid 44729867)
5. 2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition FASEB Journal 20 2006 1352 1360 (Pubitemid 44943843)
6. M.L. Capone, M.G. Sciulli, S. Tacconelli, M. Grana, E. Ricciotti, G. Renda, P. Di Gregorio, G. Merciaro, and P. Patrignani Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects Journal of the American College of Cardiology 45 2005 1295 1301 (Pubitemid 40523153)
7. F. Catella-Lawson, M.P. Reilly, S.C. Kapoor, A.J. Cucchiara, S. DeMarco, B. Tournier, S.N. Vyas, and G.A. FitzGerald Cyclooxygenase inhibitors and the antiplatelet effects of aspirin New England Journal of Medicine 345 2001 1809 1817
8. J.A. Critchley, L.A. Critchley, P.J. Anderson, and B. Tomlinson Differences in the single-oral-dose pharmacokinetics and urinary excretion of paracetamol and its conjugates between Hong Kong Chinese and Caucasian subjects Journal of Clinical Pharmacy and Therapeutics 30 2005 179 184 (Pubitemid 41583614)
9. P. Gaede, P. Vedel, N. Larsen, G.V. Jensen, H.H. Parving, and O. Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes New England Journal of Medicine 348 2003 383 (339)
10. D.K. Gehlhaar, G.M. Verkhivker, P.A. Rejto, C.J. Sherman, D.B. Fogel, L.J. Fogel, and S.T. Freer Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming Chemical Biology 2 1995 317 324
11. Gehlhaar, D.K., Bouzida, D., Rejto, P.A., 1998. Fully automated and rapid flexible docking of inhibitors covalently bound to serine proteases in evolutionary programming VII. In: Proceedings of the Seventh International Conference on Evolutionary Programming. London, UK: Springer, pp. 449-461.
12. F.M. Gengo, L. Rubin, M. Robson, M. Rainka, M.F. Gengo, D.E. Mager, and V. Bates Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis Journal of Clinical Pharmacology 48 2008 117 122 (Pubitemid 350292265)
13. P.A. Gladding, M.W. Webster, H.B. Farrell, I.S. Zeng, R. Park, and N. Ruijne The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers American Journal of Cardiology 101 2008 1060 1063
14. A. Goltsov, A. Maryashkin, M. Swat, Y. Kosinsky, I. Humphery-Smith, O. Demin, I. Goryanin, and G. Lebedeva Kinetic modelling of NSAID action on COX-1: focus on in vitro/in vivo aspects and drug combinations European Journal of Pharmaceutical Sciences 36 2009 122 136
15. K.H. Grotemeyer, H.W. Scharafinski, and I.W. Husstedt Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients Thrombosis Research 71 1993 397 403
16. T. Hohlfeld, N. Zimmermann, A.A. Weber, G. Jessen, H. Weber, K. Schrör, H.D. Höltje, and R. Ebel Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis Journal of Thrombosis and Haemostasis 6 2008 166 173
17. C.H. Hennekens, W.R. Schneider, P.R. Hebert, U.S. Tantry, and P.A. Gurbel Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to aspirin resistance American Heart Journal 159 2010 744 748
18. D. Jung, E.J. Mroszczak, A. Wu, T.L. Ling, H. Sevelius, and L. Bynum Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine Pharmaceutical Research 6 1989 62 65 (Pubitemid 19060825)
19. M. Livio, A. Del Maschio, C. Cerletti, and G. de Gaetano Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity Prostaglandins 23 1982 787 796 (Pubitemid 13238162)
20. P.J. Loll, D. Picot, O. Ekabo, and R.M. Garavito Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site Biochemistry 35 1996 7330 7340 (Pubitemid 26191283)
21. C. Luong, A. Miller, J. Barnett, J. Chow, C. Ramesha, and M.F. Browner Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2 Natural Structural Biology 3 1996 927 933 (Pubitemid 26398325)
22. M.R. Mueller, A. Salat, P. Stangl, M. Murabito, S. Pulaki, D. Boehm, R. Koppensteiner, E. Ergun, M. Mittlboeck, W. Schreiner, U. Losert, and E. Wolner Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty Thrombosis and Haemostasis 78 1997 1003 1007 (Pubitemid 27417291)
23. M. Ouellet, D. Riendeau, and M.D. Percival A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin Proceedings of the National Academy of Sciences of the United States of America 98 2001 14583 14588 (Pubitemid 33121435)
24. A. Pargal, M.G. Kelkar, and P.J. Nayak The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations Biopharmaceutics and Drug Disposition 17 1996 511 519 (Pubitemid 26267670)
25. D. Picot, P.J. Loll, and R.M. Garavito The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 Nature 367 1994 243 249 (Pubitemid 24051139)
26. I. Raz, Z. Hussein, E. Samara, and J. Ben-David Comparative pharmacokinetic analysis of a novel sustained-release dosage form of diclofenac sodium in healthy subjects International Journal of Clinical Pharmacology, Therapy, and Toxicology 26 1988 246 248
27. G. Renda, S. Tacconelli, M.L. Capone, D. Sacchetta, F. Santarelli, M.G. Sciulli, M. Zimarino, M. Grana, E. D'Amelio, M. Zurro, T.S. Price, C. Patrono, R. De Caterina, and P. Patrignani Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease Clinical Pharmacology and Therapeutics 80 2006 264 274 (Pubitemid 44313900)
28. D. Riendeau, M.D. Percival, S. Boyce, C. Brideau, S. Charleson, W. Cromlish, D. Ethier, J. Evans, J.P. Falgueyret, A.W. Ford-Hutchinson, R. Gordon, G. Greig, M. Gresser, J. Guay, S. Kargman, S. Leger, J.A. Mancini, G. O'Neill, M. Ouellet, I.W. Rodger, M. Therien, Z. Wang., JK. Webb, E. Wong, and CC. Chan Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor British Journal of Pharmacology 121 1997 105 117 (Pubitemid 27195011)
29. G. Rimon, R.S. Sidhu, D.A. Lauver, J.Y. Lee, N.P. Sharma, C. Yuan, R.A. Frieler, R.C. Trievel, B.R. Lucchesi, and W.L. Smith Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1 Proceedings of the National Academy of Sciences of the United States of America 107 2009 28 33
30. K.C. Schmitt, and M.E. Reith The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors PLoS One 6 2011 e 25790
31. M.P. Schuijt, H.W. Huntjens-Fleuren, M. de Metz, and E.J. Vollaard The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers British Journal of Pharmacology 157 2009 931 934
32. R. Storn, and K. Price Differential evolution - a simple and efficient adaptive scheme for global optimization over continuous spaces Journal of Global Optimization 11 1997 341 359 (Pubitemid 127502202)
33. D.P. Symmons, and S.E. Gabriel Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE Nature Reviews Rheumatology 7 2011 399 408
34. R. Thomsen, and M.H. Christensen MolDock: a new technique for high-accuracy molecular docking Journal of Medicinal Chemistry 49 2006 3315 3321 (Pubitemid 43830529)
35. 2 metabolism and results in an altered susceptibility to aspirin effects Platelets 11 2000 177 182 (Pubitemid 30345426)
36. Y. Yu, Y. Cheng, J. Fan, X.S. Chen, A. Klein-Szanto, G.A. Fitzgerald, and C.D. Funk Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition Journal of Clinical Investigation 5 2005 986 995 (Pubitemid 40489403)
37. D. Zhou, Q. Zhang, W. Lu, Q. Xia, and S. Wei Single- and multiple-dose pharmacokinetic comparison of a sustained-release tablet and conventional tablets of naproxen in healthy volunteers Journal of Clinical Pharmacology 38 1998 625 629 (Pubitemid 28354900)
38. N. Zimmermann, A. Wenk, U. Kim, P. Kienzle, A.A. Weber, E. Gams, K. Schrör, and T. Hohlfeld Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery Circulation 108 2003 542 547 (Pubitemid 36961167)